Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 425Leukemia, Myeloid, Acute 351Leukemia 240Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Precursor Cell Lymphoblastic Leukemia-Lymphoma 211Myeloproliferative Disorders 161Lymphoma, Non-Hodgkin 156Hodgkin Disease 135Primary Myelofibrosis 129Leukemia, Lymphocytic, Chronic, B-Cell 129Multiple Myeloma 126Leukemia, Myelomonocytic, Chronic 118Lymphoma 106Leukemia, Myeloid, Chronic-Phase 78Lymphoma, Mantle-Cell 76Lymphoma, Follicular 71Congenital Abnormalities 69Blast Crisis 69Lymphoma, Large B-Cell, Diffuse 67Leukemia, Myeloid, Accelerated Phase 66Polycythemia Vera 64Lymphoma, B-Cell, Marginal Zone 64Burkitt Lymphoma 63Hematologic Neoplasms 53Anemia, Refractory, with Excess of Blasts 52Lymphoma, Large-Cell, Immunoblastic 51Neoplasms, Plasma Cell 47Myelodysplastic-Myeloproliferative Diseases 44Thrombocythemia, Essential 40Recurrence 40

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Piebaldism × Myeloid × Clear all
NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡